USANA Health Sciences (NYSE:USNA) Shares Pass Above 200 Day Moving Average – Time to Sell?

USANA Health Sciences, Inc. (NYSE:USNA) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $19.60 and traded as high as $22.80. USANA Health Sciences shares last traded at $22.3870, with a volume of 97,300 shares traded.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on USNA. Wall Street Zen raised shares of USANA Health Sciences from a “hold” rating to a “buy” rating in a research note on Saturday, June 20th. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research note on Wednesday, June 24th. Finally, Zacks Research lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 22nd. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Reduce”.

USANA Health Sciences Price Performance

The firm has a market capitalization of $413.26 million, a price-to-earnings ratio of 47.63, a PEG ratio of 0.86 and a beta of 0.73. The business’s fifty day simple moving average is $19.71 and its 200 day simple moving average is $19.60.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.61 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.17. The company had revenue of $250.22 million for the quarter, compared to analysts’ expectations of $240.99 million. USANA Health Sciences had a net margin of 0.96% and a return on equity of 6.21%. USANA Health Sciences has set its FY 2026 guidance at 1.950-2.290 EPS. Equities research analysts expect that USANA Health Sciences, Inc. will post 2.12 earnings per share for the current fiscal year.

Insider Transactions at USANA Health Sciences

In other USANA Health Sciences news, CFO G Doug Iiekking sold 5,360 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $18.75, for a total value of $100,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joshua Foukas sold 3,791 shares of the business’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $19.82, for a total value of $75,137.62. The SEC filing for this sale provides additional information. Insiders sold a total of 17,660 shares of company stock valued at $336,579 in the last 90 days. Corporate insiders own 0.82% of the company’s stock.

Hedge Funds Weigh In On USANA Health Sciences

Large investors have recently modified their holdings of the company. Versant Capital Management Inc grew its position in USANA Health Sciences by 1,472.3% in the 2nd quarter. Versant Capital Management Inc now owns 1,588 shares of the company’s stock valued at $34,000 after purchasing an additional 1,487 shares during the period. Empowered Funds LLC increased its stake in USANA Health Sciences by 9.7% during the 1st quarter. Empowered Funds LLC now owns 66,293 shares of the company’s stock valued at $1,158,000 after purchasing an additional 5,856 shares in the last quarter. Lazard Asset Management LLC acquired a new position in USANA Health Sciences during the first quarter worth $1,265,000. Sei Investments Co. raised its holdings in USANA Health Sciences by 98.8% during the first quarter. Sei Investments Co. now owns 59,730 shares of the company’s stock worth $1,043,000 after buying an additional 29,691 shares during the last quarter. Finally, State of Wyoming bought a new position in shares of USANA Health Sciences in the first quarter valued at $57,000. 54.25% of the stock is currently owned by institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.